BioSpace News Archive

The companies will evaluate ViGeneron’s proprietary, intravitreally injected vgAAV vectors for delivering a novel therapeutic protein to develop a gene therapy treatment for a highly prevalent eye disease

Spero will assign relevant SPR206 patents to Everest Medicines in Greater China, South Korea and certain Southeast Asian countries

Tessa Therapeutics, a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, announced that the European Medicines Agency has granted PRiority MEdicines designation to the company’s lead autologous CD30 CAR-T therapy for the treatment of relapsed or refractory classical Hodgkin Lymphoma.

A new Quest Diagnostics Health Trends™ study finds that Black and Hispanic/Latinx Americans are nearly two times as likely as White Americans to say their access to COVID-19 vaccines, treatments and healthcare, once available, is worse than other racial/ethnic groups.

Havn Life to grow its partnership with the US-based veterans’ organization by funding and supporting the launch of its Canadian counterpart.

Luxel Corporation announced today that it has entered into an exclusive license agreement with Harvard University to manufacture and commercialize GridTape® for research purposes.

Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today the first patient dosed in an investigator-initiated, randomized phase II, open-label clinical trial for its antiviral alisporivir (Debio 025).

Cure Genetics announced a collaboration with Boehringer Ingelheim to develop novel Adeno-Associated Virus (AAV) vectorsleveraging Cure Genetics’ proprietary VELPTM platform to develop next-generation gene therapies.

Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Lonza announced today their agreement in support of ARU-1801, Aruvant’s one-time investigational gene therapy for sickle cell disease (SCD)

The St. Vincent Home for Children Board of Trustees and executive leadership team have announced it has hired James Keeton as its Director of Programs. Mr. Keeton joined the agency on January 11, 2021.